adebrelimab + irinotecan liposome + famitinib

This is a combination therapy consisting of three agents with distinct mechanisms of action, under investigation for the treatment of advanced solid tumors, particularly small cell lung cancer and other malignancies. **Adebrelimab** is a humanized IgG4 monoclonal antibody targeting PD-L1 (programmed death-ligand 1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. It has demonstrated efficacy in extensive-stage small cell lung cancer (ES-SCLC) when combined with chemotherapy[2][5]. **Irinotecan liposome** is a nanoliposomal formulation of the topoisomerase I inhibitor irinotecan, designed to prolong circulation time and improve tumor delivery compared to conventional irinotecan. It induces DNA damage by stabilizing the topoisomerase I-DNA complex, leading to apoptosis in rapidly dividing cells[8][10]. **Famitinib** is an orally active small molecule tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases including VEGFR2/3, PDGFR, c-Kit (stem cell factor receptor), Flt1 and Flt3. By inhibiting these kinases, famitinib blocks angiogenesis and tumor growth[7][9]. The combination aims to leverage immunotherapy (adebrelimab), cytotoxic chemotherapy (irinotecan liposome), and targeted antiangiogenic/antitumor activity (famitinib) for synergistic effects against cancer.

Brand names

Onivyde

Other names

adebrelimabirinotecan liposome injectionfamitinib